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INTRODUCTION:EMAST is a poorly understood formofmicrosatellite instability (MSI) in colorectal cancer (CRC) for
which loss ofMSH3 has been proposed as the underlyingmechanism, based on experimental studies.We aimed to
evaluate whether MSH3 loss is associated with EMAST in CRC. METHODS: A consecutive cohort of patients with
stage I-III CRC. Digital image analysis using heatmap-derived hot spots investigated MSH3 expression by
immunohistochemistry. Fragment analysis ofmultiplex PCRwas used to assessMSI and EMAST, and results cross-
examined with MSH3 protein expression. RESULTS:Of 152 patients, EMASTwas found in 50 (33%) and exclusively
in the colon.Most EMAST-positive cancers had instability at all 5 markers, and EMAST overlapped withMSI-H in 42/
50 cases (84%). The most frequently altered tetranucleotide markers were D8S321 (38.2% of tumors) and D20S82
(34.4%). Subjective evaluation ofMSH3 expression by IHC in tumor found10%negative tumor cells in all samples,
most being5%negative. Digital analysis improved the detection but showed a similar spread ofMSH3 loss (range
0.1e15.7%, mean 2.2%). Hotspot MSH3 negativity ranged between 0.1 to 95.0%, (mean 8.6%) with significant
correlation with the whole slide analysis (Spearman’s rho ¼ 0.677 P < .001). Loss of MSH3 expression did not
correlate with EMAST. CONCLUSIONS: In a well-defined cohort of patients with CRC, loss of MSH3 was not
associated with EMAST. Further investigation into the mechanisms leading to EMAST in CRC is needed.
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Microsatellite instability (MSI) is caused by defects in the mismat-
ch-repair (MMR) family of proteins [1]. This results in mosaic
populations of cells bearing microsatellite loci with diverse numbers
of repeats due to uncorrected slippages during DNA replication. Silent
or deleterious consequences arise according to the microsatellites
affected and their location within the genome. In colorectal cancer
(CRC), MSI is recognized as an alternative carcinogenic pathway
to the chromosomal instability model, with a series of clinical
and pathological implications [2]. MSI continues to be debated
as a prognostic factor in CRC [3e5], and is implicated1936-5233/19
https://doi.org/10.1016/j.tranon.2019.08.009
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subtype [6].
Elevated microsatellite alterations at selected tetranucleotides
(EMAST) is a variant of MSI described in lung, skin, prostate, and
other cancers, including CRC [7]. While MSI was initially defined as
instability at mono- and dinucleotide repeats (e.g. CAn) [8], today
commonly measured in a panel consisting exclusively of mono-
nucleotides [9], the definition of EMAST is based on instability
found in tetranucleotides (e.g. AAAGn).
MSI in CRC commonly displays loss of expression of MMR
proteins such as MLH1, MSH2, MSH6 and PMS2. The MSH2
member of theMMR family can dimerize with eitherMSH6 orMSH3
to form the MutSa or MutSb complexes [1]. The latter is believed to
have a higher affinity for repair of longer IDLs and mismatched
sequences occurring during replication, such as tetranucleotides.
MSH3 has therefore been implicated as a potential candidate to
explain instability at longer microsatellites, as found in EMAST.
In vitro, MSH3 dysfunction was associated to instability at several
tetranucleotide loci in MLH1- and MSH3-deficient CRC cell lines
via whole chromosome transfer, as well as silencing/knockdown
studies [10e12]. Additionally, it has been suggested that activity of
MSH3 could be impaired by its dislocation from the nucleus to the
cytosol, a process possibly mediated by interleukin-6 in a context of
oxidative stress in CRC cell lines [12,13]. Furthermore, the cancer
genome atlas (TCGA) consortium described MSH3 frameshift
mutationsdand not point mutationsdas common (40%) in a
subclass of CRCs defined as hypermutated and microsatellite-un-
stable [14]. Later, it was shown how MSH3, specifically in CRC,
represents a frequent target of frameshift mutation, as opposed to the
promoter hypermethylation that occurs atMLH1 in MSI CRCs [15].
The fact that theMSH3 gene contains a mononucleotide-repeat locus
could suggest that frameshift mutations in MSH3 are a consequence
of instability at mononucleotides initiated by loss of MLH1. In the
mentioned studies it was not reported whether the frameshift
mutations found in MSH3 were silent or non-silent, and their effect
on functionality of the protein can therefore not be inferred. Should
MSH3 be proven as the biological driver of EMAST, a causal
relationship between MSI and EMAST could therefore be speculated.
Thus, the relationship between MSH3 and EMAST need to be
investigated in clinical cohorts. However, to date only 3 studies in
human tissue have investigated immunohistochemical (IHC) staining
of MSH3 in patients, and are discordant in the association between
MSH3 expression with EMAST [10,16,17].
The aim of this study was to assess if MSH3 loss could explain
EMAST in colorectal cancer and, if so, to develop a standardized
method to more accurately assess protein loss in the samples.
Materials and Methods
The patient cohort was derived from the ACROBATICC project [18]
(clinicaltrials.gov identifier: NCT01762813) and is conducted in
accordance to national regulations and approved by regional ethics
committee (REK Helse Vest, #2012/742). Written informed consent
was obtained from each participant prior to inclusion in the study.
Patient Material
Formalin-fixed, paraffin-embedded (FFPE) tumor and normal
tissue derived from stage I-III surgically removed CRC was used in
this study. Appropriate slides were assessed by a certified pathologistand representative tissue blocks selected for DNA extraction,
fragment analysis and immunohistochemistry.
EMAST and MSI Analyses
FFPE blocks were selected by an experienced pathologist and 4 
10 mm sections were cut at a microtome. Automated DNA extraction
was carried out using AllPrep DNA/RNA FFPE kit (Qiagen, Hilden,
Germany) on a QiaCUBE instrument (Qiagen) according to
manufacturer's instructions. Nucleic acid concentration and purity
were measured on a NanoDrop 2000 (ThermoFischer scientific,
Waltham, USA).
Multiplex PCR reactions (one for eachMSI and EMAST) were set up
for tumor and normal DNA from each patient. TypeIT microsatellite
(Qiagen) master mix, together with a blending of 5  50-fluorescently
labeled primer pairs was used for each reaction. PCR conditions were as
follows: 50 at 95 C (initial denaturation and enzyme activation),
followed by 37 cycles of 3000 at 95 C (denaturation), 9000 at 55 (MSI) or
57 C (EMAST, annealing) and 3000 at 72 C (extension). A final
extension step for 300 at 60 C. The primers for EMAST were specific to
the tetranucleotide loci MYCL1, D20S85, D20S82, D9S242 and
D8S321 [19]. The primers for MSI were specific for BAT-26, NR-21,
NR-24 and NR-27 [9,20], which are all quasimonomorphic mono-
nucleotide repeats with a high fidelity to high-frequency MSI (MSI-H)
as shown previously [21]. To define a tumor as EMAST and/or MSI-H,
at least 2/5 markers needed to be unstable in their respective panels.
MSH3 Immunohistochemistry
Antigen retrieval and antibody dilution were optimized prior to the
study onset. From FFPE blocks, 2 mm sections were cut and mounted
onto Superfrost Plus slides (Menzel, Braunschweig, Germany). The
sections were incubated at 60 C for 1 h and then placed in the Dako
Omnis autostainer (DAKO Agilent, Santa Clara, CA, USA).
Automated protocol from the manufacturer was followed. Following
deparaffinization and rehydration, antigen retrieval was performed at
97 C for 30 minutes, and the slides were then incubated with the
primary anti-MSH3 antibody (rabbit monoclonal anti-human
MSH3; AbCam, Cambridge UK), clone EPR4334 (2), diluted
1:100 for 1 h. A peroxidase-DAB detection kit (Envisionþ, DAKO)
was used to visualize the immune-complex. Sections were then
counterstained with hematoxylin, dehydrated in increasing concen-
trations of ethanol and mounted manually.
Subjective IHC Score
Slides were evaluated and scored by an experienced pathologist for
nuclear positivity of MSH3 (given as per cent, %) blinded to MSI and
EMAST status of each case. A composite high-resolution image at 20
magnification of each slide was obtained with a Leica SCN400 scanner
and uploaded onto an internal digital image hub for image analysis.
Digital Image Analysis
To increase scoring sensitivity of MSH3 expression, digitalized
whole-slide and hotspots scoring of positiveenegative nuclei in the
tumor portion of the sections was performed with the aid of Visiopharm
Integrator System software (VIS; Visiopharm A/S, Hoersholm, Den-
mark). An image analysis algorithm using Bayesian classification
methods was built in an app-based tool which allowed for identification
of tumor tissue within the scanned slides, and for the highlighting of its
contours (Figure 1, AeC). Manual revision of each slide ensured then
rigorous exclusion of tissue folds, stroma, necrotic areas, immune and
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algorithm was then developed to allow for the marking of positive and
negative cells with colored labels (Figure 1,DeK ). A heatmap based on
the label associated with MSH3-negativity was created for each of the
whole slides (Figure 1, E-F), for unbiased placement of one 0.8 mm2
hotspots on the areas where the concentration of MSH3-negative cells
was highest within the slides (Figure 1, G-H). RelativeMSH3 negativity
(both whole-slide and hotspots) was then derived from the ratio of
negative label area and total negative and positive label areas, as
calculated via the developed classifier.
Statistical Analysis
All statistical analyses were carried out using IBM SPSS statistics v.
25. Chi-square or Fishers Exact test were used for categorical
variables. Relationship between different operators (pathologist/
digitalized whole-slide/digitalized hotspot) in the scoring of MSH3
expression were tested using the Spearman's rank order correlation.
All tests were two-tailed with statistical significance set at P < .050.
Results
Patients Characteristics
Median age was 71.5 years (range 37.0e92.0), female patients
were 85 (56%). There were 31 (20%) rectum and 121 (80%) colon
cancers, 71 (59%) of which were in the proximal tract.
Tumor stages were equally represented with 51, 51 (34%) and 50
(33%) cases for Stage I, II and III, respectively.
EMAST and MSI Analysis
EMAST was present in 50 (33%, Figure 2, A and B) and MSI-H in
44 (28%) of 152 tumors, all of which in the colon (none in the
rectum) and 90% in the proximal part of the colon. EMAST was
positively associated with MSI (42/50 EMAST we also MSI-H, 84%
overlap; P < .001), but not with tumor stage.Figure 1. MSH3 immunohistochemistry virtual image analysis process.(A
tissue is carried out, selecting a “work area”where an app-based a
stroma. This results in a highlighted region of interest (ROI, marked
basis of their positivity (green) or negativity (blue) for the MSH3 pr
slide where the highest concentration of negative cells are located
(hotspot, light blue circle) is placed and becomes the focus of theAlmost half of the cohort (45%) showed no instability at any
EMAST marker, while most EMAST-positive patients had instability
at all 5 markers (Figure 2, C and D). The most frequently mutated
marker was D8S321 (38% of tumors), followed by D20S82 (34%).
The marker with the least events in microsatellite-stable tumors (most
specific to EMAST status) was D20S85 (Table 1). Thirty-four (34)
tumors had one unstable EMAST marker and were thus classified as
EMAST-negative (Figure 2D).MSH3 Analysis
Whole slide microscopical evaluation of tumor area for MSH3 loss
found only <10% of the tumor nuclei with negative stain in all
samples, most being 5% negative (Figure 3, A and B).
Digital analysis (Figure 3) showed a similar spread (range
0.1e15.7%, mean 2.2%). Hotspot MSH3 negativity ranged between
0.1 to 95.0%, (mean 8.6%) with a significant correlation between the
two sets of measurements (Spearman's rho ¼ 0.677 P < .001),
indicating that the measurements in the hotspots are indicative of the
rest of the tumor.
MSH3 loss in hotspots was categorized in subclasses according to
different cut-off points (1%, 5%, 10%, 25% and 50%) to establish
whether a certain degree of protein loss could account for EMAST
presence. None of the subclasses correlated with EMAST status, nor
MSI-H or disease recurrence.
Heterogeneous expression of MSH3 was noted in some cases, with
nuclei staining only partially positive for the protein (Figure 3C).
However, these findings were not related to EMAST nor MSI.
Discussion
Based on a robust, automated, and digitalized protocol of IHC
assessment with a verified MSH3 antibody, this study could not
demonstrate an association between loss of MSH3 and EMAST in
CRC. While other mechanistic contributions of MSH3 to EMAST-C) An initial gross exclusion of stroma, tissue folds and normal
lgorithm is then run to specifically mark tumor cells and exclude
in blue); (D) A second app-based algorithm classifies cells on the
otein; (E-F) A heatmap is created to highlight areas on the whole
; (G) Based on the heatmap created in (E), a 0.8 mm2 round ROI
analysis; (H) Fully classified, hotspot-derived ROI.
Figure 2. EMAST analysis.Electropherograms of multiplex PCR fragment analysis are shown for (A) an EMAST-negative and (B) an
EMAST-positive patient. Arrows indicate extra PCR products at þ/ 4n bp in unstable markers. (C) Stacked bar population graph
showing frequency of instability (red) at each EMAST marker, in EMAST-positive and EMAST-negative populations. (D) bar chart
showing proportions of patients grouped by total number of unstable EMAST markers. For patients bearing only 1 marker mutated
(not EMAST, according to our thresholds) the bar is stacked to specify each marker’s abundance.
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suggests that neither protein loss, nor protein translocation (e.g. from
cytosol to nuclei) is likely to be the cause of EMAST in patients with
CRC. Thus, other mechanisms to EMAST must be considered
beyond the notion that loss of MSH3 is essential to EMAST
development [22]. Several points warrant further discussion.
The role of MSH3 expression in EMAST is debated and not yet
fully understood. Some previous mechanistic investigations have
based their experimental studies on effects seen in cancer cell lines
[12,13]. In human CRC, however, one study showed high degree of
MSH3 loss found in EMAST-positive cancers [16], but others haveTable 1. EMAST markers, genomic loci (GRCh38/hg38 assembly), repeat type ( strand), and freq
MARKER LOCUS REPEAT EMASTþ
MYCL1 *, n (%) 1p34.3 AAAG 40 (88.9)
D9S242 *, n (%) 9q33.3 AAAG 39 (84.8)
D20S82 *, n (%) 20p12.3 AAAG 41 (78.8)
D8S321, n (%) 8q24.21 AAAG 48 (82.8)
D20S85, n (%) 20q12 AAAG 26 (96.3)
* N ¼ 151.found no significant association between MSH3 loss and EMAST
[17].
One possible explanation for the discordance between the current
findings and previous results could be the source and type of antibody
used for MSH3. One previous study used a clone to MSH3 that is no
longer on the market [17], while neither the source nor clonality of
the antibody used in a second study [16] could be reproduced. A third
study used an affinity-purified rabbit polyclonal antibody [10]. The
antibody used in the current study was developed and tested for
human immunohistochemistry protocols, thus thoroughly validated
using appropriate positive and negative controls.uency of mutation.
EMAST- MSI MSS all tumors
5 (11.1) 38 (84.4) 7 (15.6) 45 (29.8)
7 (15.2) 38 (82.6) 8 (17.4) 46 (30.5)
11 (21.2) 36 (69.2) 16 (30.8) 52 (34.4)
10 (17.2) 40 (69.0) 18 (31.0) 58 (38.2)
1 (3.7) 25 (92.6) 2 (7.4) 27 (17.8)
Figure 3. Digitalized evaluation of MSH3 expression.(A) The entire cohort was scored by an experienced pathologist as >90% positive
for MSH3 (majority >95%). (B) With the help of digitalized hotspot analysis, small areas where a higher proportion of negative cells
were found in all the slides. (C) Within most MSH3-positive cells, some nuclei exhibited heterogeneous staining.
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measure IHC stains may be another issue across studies. In the
current study, in order to account for variation and involuntary
selection bias in the analysis of MSH3 expression, we constructed a
heatmap-based hotspot analysis in addition to evaluation of whole
slides. The hotspot approach is presently proving useful in the
evaluation of prognostic biomarkers with thresholds of low
expression, such as Ki67 in breast cancer [23], and has been
implemented in the Norwegian, Danish and Swedish pathology
guidelines [24e26]. However, results will still largely depend on the
robustness of the antibodies used and their reproducibility. For
MSH3, the previous studies used antibodies that are no longer on the
market, thus difficult to reproduce.
Immunohistochemistry is a complex multi-step procedure,
performed by laboratories on a range of instruments and
interpreted subjectively by pathologists according to guidelines
that are often designed for a specific diagnostic test. Autostainer
instruments and digital image analysis have reduced the discre-
pancies originating from manual experiments [27], although this
technique is still often performed manually in research labs and as
such open to a multitude of sources of variation [28,29]. To reduce
bias and misinterpretation of results to the best of our abilities, this
study employed automated staining together with objective,
automated assessment.
We found no association between MSH3 expression and EMAST
in CRC in the present study. The findings may have implications
beyond CRC as EMAST has been described in tumors other than
CRC [7]. A recent study in patients with pancreatic cancer that
described EMAST in up to 40% of patients found no inactivation of
MSH3 in the tumors [30], which is in line with the current results,
although in a different cancer type. Furthermore, MSH3 frameshift
mutations were found to be specific to CRC, but not for endometrial
cancer [15], which is also known for harboring high levels of EMAST
[31]. These observations, taken together with the results of this study
and the general disagreement in the literature, discourage the
proposed role of MSH3 loss as a universal biological mechanism
underlying EMAST.
The large overlap of MSI and EMAST in CRC found in the
current study correlates well with results from the literature [17].
EMAST could represent an exacerbation of MSI rather than a
separate occurrence. In the current study we found EMAST to
occur in colon cancers and to be associated with MSI features, asdescribed previously [19]. Shared features between MSI and
EMAST include prevalence in the proximal part of the colon and,
in the case of the present study, an absence or low prevalence in
rectal cancers. Two reports [16,32] describe a high prevalence of
EMAST among rectal cancer patients, however in one (a
rectum-only study) EMAST prevalence was higher in African
American than Caucasian patients [32]. In the second report,
describing 61% of rectal cancers as EMAST, the cohort was based
on patients of Asian ethnicity [16]. In contrast, the present cohort
consists predominantly of Caucasian patients. Considering the
documented variation of MSI-H across demographic factors such
as gender and ethnicity [33], EMAST might well follow a similar
pattern, thus explaining discrepancy in rectal distributions. The
current results are nonetheless consistent with other studies
[16,17,34] finding EMAST prevalently in colon, and more
specifically in the proximal part of the colon.
In conclusion, the mechanism leading to genomic instability in
tetranucleotides and expressed as EMAST is still largely unknown at
present. Indeed, EMAST may, as suggested for conventional MSI, be
related to epigenetic mechanisms that occur with aging (e.g. epigenetic
loss of DNA repair mechanisms). EMAST may thus represent an
epiphenomenon of age and tumorigenesis rather than a specific
tumor-driving trait per se. On the other hand,MSI-induced frameshifts
could affect MSH3 functionalitydand lead to EMASTdin ways that
the antibody used in this study could not highlight. Further
investigations into the mechanisms of EMAST is warranted.References
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